### **ENROLLMENT FORM**

Please complete and fax to 1-844-475-8931 For assistance or additional information, call 1-844-VELOXIS, M-F, 9 am - 7 pm ET.



## **Enrolling in Veloxis Transplant Support**

Veloxis has created the Veloxis Transplant Support program to assist patients in obtaining access to Veloxis medications. Applications are reviewed and eligibility is verified. Determinations are made on a case-by-case basis using pre-determined eligibility requirements regarding coverage and financial criteria.

After the Form has been submitted, including Financial Documentation and Insurance Cards, your Veloxis Transplant Support (VTS) Specialist will review the application and then notify both provider and patient of next steps.

#### **ENROLLMENT INSTRUCTIONS**

 Patient completes Page 3 of this form, including patient or patient representative's signature

Financial disclosure, including verification of income, is only required if applying for the Patient Assistance Program.

All other Veloxis Transplant Support services may be obtained without financial disclosure, but will still require the patient consent signature on the bottom of Page 3.

- Fax complete application package to Veloxis Transplant Support at 1-844-475-8931
  - ✓ Page 2 with Prescriber's Signature
  - ✓ Page 3 with Patient's or Patient Representatives' Signature
  - ✓ Copies of both sides of all Insurance Cards
  - ✓ If applying for the Patient Assistance Program, please sign the optional consent on Page 3 to authorize the electronic income verification and expedite the process through Experian Health **OR** provide income verification documents with this application.

If the application is incomplete, VTS will attempt to contact the patient and provider to request the missing information or documentation.

Requesting the following, please check all that apply:	
☐ Benefits Investigation	
☐ Bridge Supply	

# Patient Assistance Program (PAP) enrollment (based on eligibility; please include the appeal denial if you have it to expedite the process)

#### PATIENT ASSISTANCE PROGRAM DETAILS

Patients enrolled in the Patient Assistance Program are approved for a maximum of 12 months of eligibility at a time and must reapply to validate their eligibility annually. VTS will contact you to re-validate your eligibility for the Patient Assistance Program before the current eligibility period expires.

Note for Medicare Part D Participants: When interfacing with a Medicare Part D beneficiary, the Veloxis Patient Assistance Program will operate outside of the Medicare Part D benefit. Any assistance provided to a patient for drugs that would have been covered under their Medicare Part D plan will not count as an incurred cost that would be applied toward the enrollee's True Out-of-Pocket Costs (TrOOP) balance or total drug spend.



## **ENROLLMENT FORM**

#### Please complete and fax to 1-844-475-8931

accurate. I attest that I am not on the HHS/OIG list of Excluded Individuals.

Prescriber's Printed Name

For assistance or additional information, call 1-844-VELOXIS, M-F, 9 am - 7 pm ET.

# **Veloxis | Transplant Support**



Call 1-044-	VELUAIS,	м-г, 9 am - / pm	I ⊑ I .								
	1. First Name		2. Midd	3	3.Last Name			4. Date of Birth (MM/DD/YYY			
	5. Home Address				6.City			7. State	е	8	3. Zip Code
PATIENT CONTACT	9. Home Phone #			10. Cell Phone #				11. Email			
INFORMATION	12. Preferred contact method (select one):			Phone Call			☐ Text		[	☐ Email	
	13. Preferr	ed time to contact (se	elect one):	Morning			☐ After	noon	[	☐ Evening	<u> </u>
	14. OK to T	ext (select one):	☐ YES	□ NO	1	5. OK	to leave	voicemail (selec	t one): [	☐ YES	□ NO
	16. Preferr	ed Language:									
	17. Pharma	acy Benefit Plan Name	e:								
	17(a) Policy	y Holder Name:				17(b). Insurance Phone #:					
	17(c). RX B	IN:	17(d). RX F	PCN: 17(e). ID#:			. ID#:		17(f).	Rx Group	#:
PATIENT INSURANCE INFORMATION	18. Patient has (select one): ☐No insurance			☐Medicare B	☐ Medicare Advantage ☐ Medicaid			Medicaid □Pri	vate/Com	mercial	☐ Government (TriCare/VA)
(please attach		19(a). Primary Insul	(a). Primary Insurance Name:				20(a). Se	condary Insuran	ce Name:		(means) vily
copies of patient applicant's insurance	19. Primary Insurance	19(b). First Nam Policy Holder Name:	ne	Last Name		ondary	20(b). Policy Holder Name:	First Name			Last Name
cards)		19(c). Insurance Pl		Insur	ance		surance Phone #	<b>!</b> :			
		19(d). Policy ID #:					20(d). Po	licy ID #:			
		19(e). Group ID #:					20(e). Group ID #:				
	21. First Na	ame		22. Last Name			2	23. Specialty			
	24. Title (se	elect one):	1D □ DO	□ NP	□PA		other(spec	ify):			
	25. NPI #:	,			26	S. Tax II	) #:				
	27. Practice	e Name:									
HEALTHCARE	28. Practice				29. City:		30. Sta	te: 3	31. Zip Code:		
PROVIDER NFORMATION	32. Practice Office Contact Title:						32(a). Na	ıme:			
	32(b). Offic	e Phone:	Phone:	32(d). Contact Email:					32(e). Fax:		
	32(f). Preferred method of contact (select one): ☐ Office Phone						Phone	☐ Email	□ Fax		
					:	32(g). C	K to text C	ell Phone (select	one):	□YES	□NO
	33. Diagnos	sis (select one): $\square$ ZS	94.0 Kidney tra	nsplant status (IC	D-10)		☐ Other (	specify)			
PATIENT	34. Date of Transplant: 35. Did Medicare pay for transplant (select one)?								□ YES □ NO		
CLINICAL NFORMATION	36. Estimated total daily dose of ENVARSUS XR® (tacrolimus extended-release tablets):										
	37. Has a 30-day voucher of ENVARSUS XR® (tacrolimus extended-release tablets) been provided to the patient? (select one):										
							37(a). It	f YES, Date provi	ded:		
HEALTHCARE I	PROVIDER C	ERTIFICATION									
(provided herein) access to ENVAR necessary to enr	to Veloxis Ph SUS XR® (tac oll my patient	ow, I acknowledge and narmaceuticals and its rolimus extended-rele t in the VTS program s ed nor will receive any	s service provide ase tablets). The hould the patier	ers, agents, and ac e Veloxis Transpla nt applicant meet	dministrato Int Support the eligibilit	s (colle ("VTS") y criteri	ctively, the program m a. I underst	"Companies") to nay use and disclotand that I am un	assist the ose the pa der no obl	patient a tient appli igation to	pplicant in obtaining icant information as prescribe ENVARSU

FDA approved use based on my independent medical judgment that ENVARSUS XR® is medically necessary for the patient and that all information provided on the form is

Prescriber's Signature

## **ENROLLMENT FORM**

Please complete and fax to 1-844-475-8931 For assistance or additional information, call 1-844-VELOXIS, M-F, 9 am - 7 pm ET.





can r o44	VLLOXIO, IV	ii, 5 aiii 7 piii	L1.					
	38. Total annu	al household income	e: \$					
	39. Sources of	income (select all th	at apply):					
PATIENT	☐ Salary Wages	Social Security Income (SS, SSI, SSDI)	Unemployment Compensation	☐ Pension/ Retirement	☐ Veterans Benefits	☐ Workers' Compensation	☐ Alimony/ Child Suppor	Other:
FINANCIAL INFORMATION	40. Total numb	per of people in hous	ehold dependent	on household inc	ome (includir	ng Patient):		'
	forms of docume the two most reco	ntation to provide proof	of household income inployment or disabili	e reported in this Se ty statements etc. <b>I</b>	ection include the	ne most recent copy iding proof of incon	of US federal tax	ent Assistance Program (PAP). Acceptable return, Social Security income statements, n, you have the option to consent to
PATIENT AUTH	HORIZATION FO	OR ELECTRONIC INC	COME VERIFICAT	<b>ION</b> (optional, bu	t may reduce	enrollment revie	w time)	
By providing my s (collectively, the "Companies to use additional financia financial screenin, revocation to patie through this author X_	ignature below, I, Companies") unde and disclose my i al documentation i g process. I under entsupport@veloxi vrization before the	the patient applicant, under the Fair Credit Reportion of the fair Credit Reportion of the fair the fa	Inderstand that I am ng Act, authorizing the e purpose of determi quested. I understan d to a copy of this a t my revocation mus notice of my written i	providing "written in the Companies to obtaining my eligibility to did that I must affirm the cuthorization upon returned to made in writing to the made in writing the companies of the companie	instructions" to ain information o enroll and par atively agree to equest. I unde g. I understand	Veloxis Pharmaceu from my credit profi ticipate in the Veloxi all the terms in this rstand that I may re that my revocation s	ticals and its ser ile or other inform is Transplant Sup authorization in evoke this author shall not apply to	vice providers, agents, and administrators lation from Experian Health. I authorize the port (VTS) program. I also agree to provide order to proceed in this optional electronic ization at any time by sending a notice of any information already used or disclosed
Relationship to	·	self ☐ legal gu	_		rioprosentati	ves dignature	•	out.
		OR USE AND DISCLO						
information, included communicable distant administrators and (3) contact me by federal privacy l	ding information a eases (HIV, hepati s (collectively, the e to evaluate thera aw and applicable	about my insurance be tis), drug/alcohol abuse "Companies") to: (1) est py and the effectiveness	enefits, prescriptions, , mental health, gene ablish my benefit elig s of the VTS program. subject to redisclosur	, medical condition tic testing, etc.), (colgibility; (2) provide sull understand that or e. I understand that	and history, a llectively, "Perso upport services, nce my Persona	dherence to my tre onal Information") wi including facilitating I Information has bee	eatment, my geneith Veloxis Pharmage the provision of en disclosed to the	are, and disclose my personal and health eral health, and my sensitive health (e.g. aceuticals and its service providers, agents, Veloxis Pharmaceuticals medication to me; e Companies, it may no longer be protected any specialty pharmacies providing support
understand that if authorization at ar end my participation the VTS program re entities through the	refuse to sign this ny time by sending on in the VTS progreceived notice of r his authorization be	authorization, I will not a notice of revocation to ram. I understand that r my written revocation. I	be eligible to particip patientsupport@velony revocation shall no understand that my reserved notice of	pant in the VTS progoxis.com. I understant apply to any of my revocation shall not from written revocat	ram if I meet th nd that my revo Personal Informapply to any of ion. I understa	e eligibility criteria. I cation must be mad- mation that has alrea my Personal Informa nd my authorizing s	understand that e in writing. I und ady been used or ation that has alre	or enrollment in a health plan. However, I if I give my authorization, I may revoke my erstand that revoking this authorization will disclosed through this authorization before ady been used or disclosed by the covered ain in effect until I am no longer eligible to
XPatient's or Pati Relationship to	· _	tives' Printed Name self		itient's or Patient egiver	Representati	ves' Signature	)	oate
PATIENT ATTE	STATION OF N	O INSURANCE COV	FRAGE (if applica	ble)				
		he patient applicant, at	· · · · · ·		urance coveras	re.		
by providing my of	g, ., c	o patient applicant, at	asset and sorting that	. Have no hould his	a.a	,0.		
X Patient's or Pati	ient Representa	tives' Printed Name	X_ Pa	tient's or Patient	Representati	ves' Signature		C Date
		self ☐ legal gu						
PATIENT DECL	ARATION							
By providing my si reviewed and relie qualify for the VTS free medication is form, modify or dis	gnature below, I, t d upon to determin program. I unders contingent upon m scontinue the VTS	ne my eligibility for enrol tand that the VTS progra ny ability to meet the VTS	Ilment in the Veloxis T am may request addi program eligibility cri ity criteria, or termina	Fransplant Support ( tional documentatio iteria. I understand V ate my enrollment in	"VTS") program in from me to ve eloxis Pharmac the VTS progra	. I understand that c erify my financial or i euticals reserves the	ompleting this en nsurance informa e right at any time	I understand that such information will be rollment form does not guarantee that I will tion, and that any assistance in the form of and without notice to modify the enrollment onsible for notifying the VTS program if my
or government pro drugs. I agree I will	gram, including Mo I notify my insuran igible for the VTS p	edicare Part D Plans, or ce provider of my receip rogram, the Companies	seek to have Veloxis of Veloxis Pharmace	Pharmaceutical med euticals medication(	dication(s) or ar s) provided thro	ny cost associated wi bugh the VTS progran	ith it counted as p m. I understand a	any insurance provider, payer, health plan, art of my out-of-pocket cost for prescription nd agree that if I am enrolled in a Medicare harmaceuticals medication supplied by the
X			X_					
Patient's or Pati Relationship to	· _	tives' Printed Name self 🔲 legal gu	_	tient's or Patient egiver	Representati	ves' Signature	]	Oate Control of the C
PATIENT TELE	PHONE CONSU	IMER PROTECTION	ACT CONSENT	optional)				
By providing my si	gnature below, I, t	he patient applicant, co	onsent to receive enr	ollment status upda				e. Message and data rates may apply. of participation in the VTS program.
X			X				>	
Patient's or Pat	ient Representa	tives' Printed Name	Pa	tient's or Patient	Representati	ves' Signature		Date

□ caregiver

☐ legal guardian

Relationship to Patient:

□ self